Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 340

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 340
---
-month periods ended June 30, 2024 and 2023            
 Condensed consolidated unaudited statements of financial position at June 30, 2024 and December 31, 2023                              | Page 
 F-1  
 F-2  |
|:--------------------------------------------------------------------------------------------------------------------------------------|:-----|
| Condensed consolidated unaudited statements of cash flows for the six-month periods ended June 30, 2024 and 2023                      | F-3  |
| Condensed consolidated unaudited statements of changes in equity for the six-month periods ended June 30, 2023 and 2024               | F-5  |
| Notes forming part of the condensed consolidated unaudited interim financial information for the six month period ended June 30, 2024 | F-6  |

| 172 |

<div align='center'>BIODEXA PHARMACEUTICALS PLC

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</div>

|                                                                                                     | Page |
| Report of Independent Registered Public Accounting Firm (Forvis Mazars LLP, London, United Kingdom, 
 PCAOB ID 1401)                                                                                      | F-21 |
| Consolidated statements of comprehensive income for the years ended 31 December 2023, 2022 and 2021 | F-23 |
| Consolidated statements of financial position at 31 December 2023, 2022 and 2021                    | F-24 |
| Consolidated statements of cash flows for the years ended 31 December 2023, 2022 and 2021           | F-26 |
| Consolidated statements of changes in equity for the years ended 31 December 2023, 2022 and 2021    | F-28 |
| Notes forming part of the consolidated financial statements                                         | F-31 |

| 173 |

Consolidated Statements of Comprehensive Income

For the year six month period ended June 30

|                                                                   |     | Note |     | 2024 unaudited £’000 |    |     | 2023 unaudited £’000 |    |
| Revenue                                                           |     |      |     |                    - |    |     |                  298 |    |
| Research and development costs                                    |     |      |     |               (2,189 | )  |     |               (2,251 | )  |
| Administrative costs                                              |     |      |     |               (2,034 | )  |     |